Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 7/2007

01-07-2007 | Brief Report

Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

Authors: Francesca Bellisai, Chiara Giannitti, Alessandro Donvito, Mauro Galeazzi

Published in: Clinical Rheumatology | Issue 7/2007

Login to get access

Abstract

We describe two cases of rheumatoid arthritis (RA) patients and concomitant hepatitis C virus infection (HCV), treated with cyclosporine A (CsA) and anti-TNF-α agents. SGOT/SGPT and HCV-RNA serum levels remained unchanged longer than 1 year of treatment. No side effects were registered. We suggest that combination therapy with CsA and TNF-α blockers should be considered safe and well-tolerated in the treatment of HCV-positive RA patients.
Literature
1.
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintman G; LIS2T Study Group (2004) Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplant Proc 77:1632–1638PubMedCrossRef
2.
Casanovas Taltavull T (2004) Impact of Cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant Proc 36:S291–S294CrossRef
3.
Nakamuta M, Kohjima M, Fukushima M, Morizono S, Kotoh K, Kobayashi N, Enjoji M (2005) Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. Transplant Proc 37:4598–4602PubMedCrossRef
4.
Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M (2003) Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 38:567–572PubMed
5.
Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288PubMedCrossRef
6.
Galeazzi M, Bellisai F, Manganelli S, Morozzi G, Sebastiani GD (2006) Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 5(7):493–498PubMedCrossRef
7.
Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013–3022PubMedCrossRef
8.
Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078–1082PubMedCrossRef
9.
Duvoux C, Mennecier D, Pageaux G (2002) Immunosuppression with tacrolimus and absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus graft reinfection. In: International Society of Transplantation Congress, abstract no. 2652
10.
McCaughan GW (2004) Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 78:1413–1414PubMedCrossRef
11.
Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M (2005) Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 129:1031–1041PubMedCrossRef
12.
Miura H, Itoh Y, Matsumoto Y, Tani M, Tanabe N, Isonokami M, Kurachi K, Kozuka T (1999) Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol 38:310–314PubMedCrossRef
13.
Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S (1998) Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111:269–277PubMedCrossRef
14.
Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY (1997) Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 42:2487–2494PubMedCrossRef
15.
Fukuda R, Ishimura N, Ishihara S, Chowdhury A, Morlyama N, Nogami C, Miyake T, Niigaki M, Tokuda A, Satoh S, Sakai S, Akagi S, Watanabe M, Fukumoto S (1996) Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 16:390–399PubMed
Metadata
Title
Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection
Authors
Francesca Bellisai
Chiara Giannitti
Alessandro Donvito
Mauro Galeazzi
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0412-1

Other articles of this Issue 7/2007

Clinical Rheumatology 7/2007 Go to the issue

Case Report

Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate

Case Report

Vasculitis in siblings with familial Mediterranean fever: a report of three cases and review of the literature

Original Article

Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids

Case Report

Liposynovitis prepatellaris in athletic runner (Hoffa's syndrome): case report and review of the literature

Brief Report

Meta-analysis is no substitute for a comprehensive national registry

Case Report

Scalp necrosis: a rare complication of temporal arteritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits